BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21250697)

  • 1. A multiscale simulation system for the prediction of drug-induced cardiotoxicity.
    Obiol-Pardo C; Gomis-Tena J; Sanz F; Saiz J; Pastor M
    J Chem Inf Model; 2011 Feb; 51(2):483-92. PubMed ID: 21250697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S; Wiśniowska B; Brandys J
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in computational prediction of HERG blockage.
    Wang S; Li Y; Xu L; Li D; Hou T
    Curr Top Med Chem; 2013; 13(11):1317-26. PubMed ID: 23675938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity.
    Anwar-Mohamed A; Barakat KH; Bhat R; Noskov SY; Tyrrell DL; Tuszynski JA; Houghton M
    Toxicol Lett; 2014 Nov; 230(3):382-92. PubMed ID: 25127758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
    Aronov AM
    J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands.
    Coi A; Bianucci AM
    J Mol Graph Model; 2013 Nov; 46():93-104. PubMed ID: 24185260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico prediction of hERG inhibition.
    Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
    Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel structure-based virtual screening model for the hERG channel blockers.
    Du L; Li M; You Q; Xia L
    Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational investigations of hERG channel blockers: New insights and current predictive models.
    Villoutreix BO; Taboureau O
    Adv Drug Deliv Rev; 2015 Jun; 86():72-82. PubMed ID: 25770776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
    Narayana Moorthy NS; Ramos MJ; Fernandes PA
    Curr Drug Targets; 2013 Jan; 14(1):102-13. PubMed ID: 23061466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
    Schwoerer AP; Blütner C; Brandt S; Binder S; Siebrands CC; Ehmke H; Friederich P
    Anesthesiology; 2007 May; 106(5):967-76. PubMed ID: 17457128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.
    Du-Cuny L; Chen L; Zhang S
    J Chem Inf Model; 2011 Nov; 51(11):2948-60. PubMed ID: 21902220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds.
    Moorthy NS; Ramos MJ; Fernandes PA
    SAR QSAR Environ Res; 2012 Jul; 23(5-6):521-36. PubMed ID: 22452318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
    Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
    J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
    Schmidtke P; Ciantar M; Theret I; Ducrot P
    J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interactions between hERG potassium channel and blockers.
    Du L; Li M; You Q
    Curr Top Med Chem; 2009; 9(4):330-8. PubMed ID: 19442204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore modeling for hERG channel facilitation.
    Yamakawa Y; Furutani K; Inanobe A; Ohno Y; Kurachi Y
    Biochem Biophys Res Commun; 2012 Feb; 418(1):161-6. PubMed ID: 22244872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive models for HERG channel blockers: ligand-based and structure-based approaches.
    Thai KM; Ecker GF
    Curr Med Chem; 2007; 14(28):3003-26. PubMed ID: 18220737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug block of the hERG potassium channel: insight from modeling.
    Stansfeld PJ; Gedeck P; Gosling M; Cox B; Mitcheson JS; Sutcliffe MJ
    Proteins; 2007 Aug; 68(2):568-80. PubMed ID: 17444521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.